ArticleInternational medical case reports journal2025
Metronomic Chemotherapy in the Treatment of Infantile Parotid Hemangioma - A Case Report.
Article in International medical case reports journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Infantile hemangiomas (IH) are the most common tumors in infancy and childhood. They are characterized by a fast proliferation phase followed by gradual involution. While most IHs follow a predictable course, those involving the parotid gland pose unique diagnostic and therapeutic challenges due to their location and potential for functional impairment. This case illustrates an unusual example of unilateral parotid hemangioma with prolonged growth, requiring alternative management strategies. Case Presentation: A two-month-old girl presented with a large unilateral parotid hemangioma, first noted on the 15th day of life, which had been rapidly increasing in size. Oral propranolol was initially prescribed, but treatment was not started by the parents, and the patient was lost to follow-up. At 3.5 months of age, the patient underwent an unplanned cosmetic surgical excision at a rural hospital, which resulted in facial nerve paresis and functional facial asymmetry. She re-presented at 7 months with a markedly enlarged lesion. Propranolol (3 mg/kg/day) was reinitiated; however, despite dose escalation, the hemangioma remained unresponsive. Systemic corticosteroids (prednisolone, 1-3 mg/kg/day) at 8 months were added, but the lesion continued to progress. At 9 months of age, metronomic chemotherapy with vinblastine (1 mg/m² IV every 3 days) and cyclophosphamide (50 mg/m² orally for 10 days) was introduced under clinical supervision. This combination resulted in significant tumor regression, as confirmed by serial imaging and clinical examination. Conclusion: This case reflects the challenges of managing IHs that do not respond to standard treatment guidelines. Early surgical intervention is contraindicated when other alternative medical treatment methods are available. Otherwise, it might result in significant complications, highlighting the importance of conservative management and adherence to treatment protocols. Metronomic chemotherapy has shown to be a useful option for patients who do not respond to standard beta-blockers and corticosteroids.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.